Gilead Sciences (GILD) Stock Price
Gilead Sciences Price
Over the last 19 years Gilead Sciences grew revenue by 12.7% annually, reaching 29.44 B USD. Earnings per share have grown at 12.1% per year over the last 18 years. For Gilead Sciences, the net margin of 28.9% is up versus 22.8% a few years ago. At today's price the dividend yield works out to roughly 1.89%. The payout ratio is around 47% of earnings. The dividend has grown at 9.4% per year over the past 10 years. The consensus 12-month price target for Gilead Sciences is 155.00 USD, about 7.4% below where the stock trades today. Of 36 analysts, 30 rate the stock a buy — an overall Buy consensus.
Gilead Sciences stock price
Access this data via the Eulerpool API
100,000 free requests/mo · no credit card
Gilead Sciences business model & stock analysis
Frequently asked questions about Gilead Sciences
Gilead Sciences Inc is a biopharmaceutical company with a diversified business model. Its primary focus is on the research, development, and commercialization of innovative medications to treat and prevent life-threatening diseases. Gilead operates in multiple therapeutic areas, including HIV/AIDS, liver diseases, hematology/oncology, respiratory, cardiovascular, and viral infections. The company's business model revolves around discovering and designing new drugs, conducting clinical trials, obtaining regulatory approvals, manufacturing, marketing, and distribution of its pharmaceutical products. Through strategic collaborations and acquisitions, Gilead continuously expands its portfolio and aims to improve the quality of life for patients worldwide.
Gilead Sciences Inc is primarily active in the pharmaceutical industry.
The main competitors of Gilead Sciences Inc in the market include renowned companies like AbbVie, Bristol-Myers Squibb, and Merck & Co. These pharmaceutical giants operate in similar therapeutic areas and engage in the research, development, and commercialization of innovative medicines. At present, Gilead Sciences Inc faces competition in the fields of antiviral drugs, liver diseases, HIV/AIDS treatments, and oncology from these prominent industry players.
Gilead Sciences Inc, a leading biopharmaceutical company, was founded in 1987 by Dr. Michael L. Riordan in Foster City, California, USA. It specializes in discovering, developing, and commercializing innovative medicines to address unmet medical needs. Gilead has a rich history of pioneering breakthrough treatments for critical diseases such as HIV/AIDS, hepatitis, and other viral infections. With a mission to advance patient care globally, Gilead has expanded its portfolio through strategic acquisitions and collaborations, constantly striving to improve and save lives. Today, Gilead Sciences Inc remains committed to research, development, and manufacturing of transformative therapies across various therapeutic areas.
Gilead Sciences Inc has achieved several significant milestones throughout its history. It gained global recognition with the development of groundbreaking antiviral drugs such as Sovaldi and Harvoni, revolutionizing the treatment of hepatitis C. The company also made remarkable progress in the field of HIV, introducing a single-tablet regimen named Genvoya, providing convenient and effective therapy. Gilead Sciences Inc further expanded its therapeutic areas, bringing forth innovative treatments for life-threatening diseases like cancer and autoimmune disorders. Moreover, it received approval for its antiviral drug, remdesivir, as a treatment for COVID-19. These milestones solidify Gilead Sciences Inc's position as a leader in the pharmaceutical industry.
Gilead Sciences Inc is primarily present in various countries and regions worldwide. Some key locations where the company has a strong presence include the United States, Europe (including countries like Germany, France, and the United Kingdom), Asia-Pacific (including countries like Japan, Australia, and China), and Latin America (including countries like Brazil and Mexico). With a global footprint, Gilead Sciences Inc operates in multiple markets, providing its innovative biopharmaceutical products and therapies to patients across different continents.
Gilead Sciences Inc represents a commitment to improving the lives of patients through innovative research and development in the fields of life sciences and biotechnology. Their corporate philosophy emphasizes a patient-centered approach, scientific integrity, and a drive to address unmet medical needs. Gilead Sciences Inc focuses on developing breakthrough therapies and treatments to combat diseases such as HIV/AIDS, viral hepatitis, and other challenging illnesses. They prioritize collaboration with healthcare professionals and stakeholders to ensure the delivery of high-quality healthcare solutions. With a strong emphasis on scientific excellence and a dedication to addressing global health challenges, Gilead Sciences Inc continues to make a significant impact in the industry.
Analysts currently set an average price target of 153.33 USD for the Gilead Sciences stock (median: 155.00 USD), implying -8.4 % versus the latest price. The consensus is based on 36 analyst ratings.
36 analysts currently rate the Gilead Sciences stock: 30 recommend buying, 6 holding and 0 selling. For 2026, analysts expect Gilead Sciences to generate revenue of 30.78 B USD and earnings per share of -0.40 USD.
Converted at the current exchange rate, the Gilead Sciences share trades at 149.62 EUR (167.47 USD).
The Gilead Sciences share (GILD) is listed on 10 stock exchanges, including: NASDAQ (GILD), London (0QYQ.L), SIX (Zürich) (GILD.SW), XETRA (GIS.DE), Frankfurt (GIS.F), München (GIS.MU), Düsseldorf (GIS.DU), Hamburg (GIS.HM).
Gilead Sciences Inc is a biopharmaceutical company that develops innovative therapies for serious diseases such as HIV, hepatitis B and C, cancer, lung and liver diseases. The company is headquartered in Foster City, California and has been publicly traded since 1987. Gilead operates worldwide and has offices in more than 30 countries. The business model of Gilead Sciences is based on the development, manufacturing and marketing of innovative drugs. The company specializes in discovering chemicals that enable effective treatment of diseases. In recent years, Gilead Sciences has focused on the development of drugs for hepatitis C and HIV, which has contributed to significant revenue growth. Gilead Sciences' products are divided into three divisions: 1. Infectious Diseases: This division includes drugs for the treatment of HIV, hepatitis B and C, and other infectious diseases. The most well-known and successful drug is Viread, used for the treatment of HIV and hepatitis B. Another promising drug is Harvoni, a combination of two active ingredients used to treat hepatitis C. 2. Oncology: This division includes drugs for the treatment of various types of cancer, such as multiple myeloma, non-Hodgkin's lymphoma, and chronic lymphocytic leukemia. The most well-known drug is Revlimid, used for the treatment of multiple myeloma and other types of cancer. 3. Inflammatory and respiratory diseases: This division includes drugs for the treatment of conditions such as rheumatoid arthritis, Crohn's disease, and emphysema. The most well-known drug is Remicade, used for the treatment of inflammatory bowel disease. In recent years, Gilead Sciences has established itself as a leading biopharmaceutical company through significant acquisitions and acquisitions. For example, in 2017, Kite Pharma, a company specializing in cancer immunotherapy, was acquired for $11.9 billion. This acquisition allowed Gilead Sciences to expand its portfolio of oncology drugs and strengthen its market position. Gilead Sciences' business model is based on a strong research and development department that continuously discovers and introduces new drugs to the market. Gilead Sciences has a broad pipeline of drugs in development to provide effective treatment for serious diseases to patients worldwide. The company works closely with regulatory authorities to expedite the approval of new drugs. Overall, Gilead Sciences Inc is an innovative and successful biopharmaceutical company specializing in the development and marketing of drugs for the treatment of serious diseases. The company has established itself as a leading provider in this field in recent years and will continue to play a crucial role in the development of new therapies in the future.
The expected revenue of Gilead Sciences is 30.78 B USD. This figure is based on current financial data and reflects the company's business performance.
The expected profit of Gilead Sciences is -500.02 M USD. The net profit reflects the company's profitability after deducting all expenses.
The price-to-earnings ratio (P/E) of Gilead Sciences is currently -419.67. The P/E ratio compares the current share price to the earnings per share and helps investors assess the valuation of the Gilead Sciences stock.
The price-to-sales ratio (P/S) of Gilead Sciences is currently 6.82. The P/S ratio compares the market capitalization to the annual revenue and serves as a valuation metric for the Gilead Sciences stock.
The Eulerpool Quality Score for Gilead Sciences is 5/10.
The ISIN of Gilead Sciences is US3755581036. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.
The WKN of Gilead Sciences is 885823. The WKN (Wertpapierkennnummer) is a six-digit German security identification number.
The ticker of Gilead Sciences is GILD. The ticker symbol is used to trade Gilead Sciences shares on the stock exchange.
Gilead Sciences stock
Gilead Sciences Peer Group
Gilead Sciences Ticker
Gilead Sciences FIGI
All fundamentals and in-depth analysis of Gilead Sciences
Our stock analysis for Gilead Sciences stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Gilead Sciences. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.